Author Archive
Entries by Samer Shamout, Kevin Carlson, Hilary L. Brotherhood, Trafford Crump, Richard Baverstock
Prostate‐specific membrane antigen theranostics in advanced prostate cancer: an evolving option
Objectives To review current data for the role of prostate specific membrane antigen (PSMA) radioligand therapy (RLT) for patients with advanced prostate cancer. This review provides an update for multidisciplinary teams on the current and potential future applications of theranostics in prostate cancer. Methods Narrative review focussing on PSMA as a target for RLT, and […]
Rezum water vapour therapy: Promising early outcomes from the first UK series
Abstract The management of symptomatic BPH is evolving and there is now an expanding portfolio of minimally invasive surgical therapies (MIST). These provide an attractive option for men looking for meaningful improvement in urinary symptoms whilst avoiding the risks of adverse effects, particularly with regards to maintaining sexual function.
Multi‐centre exploratory study of the impact of urinary incontinence in the six weeks after catheter removal following radical prostatectomy
Abstract The management of symptomatic BPH is evolving and there is now an expanding portfolio of minimally invasive surgical therapies (MIST). These provide an attractive option for men looking for meaningful improvement in urinary symptoms whilst avoiding the risks of adverse effects, particularly with regards to maintaining sexual function.
Risk stratification for the prediction of overall survival could assist treatment decision‐making at diagnosis of castration‐resistant prostate cancer: a multicentre collaborative study in Japan
Abstract The management of symptomatic BPH is evolving and there is now an expanding portfolio of minimally invasive surgical therapies (MIST). These provide an attractive option for men looking for meaningful improvement in urinary symptoms whilst avoiding the risks of adverse effects, particularly with regards to maintaining sexual function.
The cost‐effectiveness of transurethral resection of the prostate vs thulium laser transurethral vaporesection of the prostate in the UNBLOCS randomised controlled trial for benign prostatic obstruction
Abstract The management of symptomatic BPH is evolving and there is now an expanding portfolio of minimally invasive surgical therapies (MIST). These provide an attractive option for men looking for meaningful improvement in urinary symptoms whilst avoiding the risks of adverse effects, particularly with regards to maintaining sexual function.
Transurethral en bloc submucosal hydrodissection vs conventional resection for resection of non‐muscle‐invasive bladder cancer (HYBRIDBLUE): a randomised, multicentre trial
Abstract The management of symptomatic BPH is evolving and there is now an expanding portfolio of minimally invasive surgical therapies (MIST). These provide an attractive option for men looking for meaningful improvement in urinary symptoms whilst avoiding the risks of adverse effects, particularly with regards to maintaining sexual function.
A new Editorial Team for the BJU International…
Abstract The management of symptomatic BPH is evolving and there is now an expanding portfolio of minimally invasive surgical therapies (MIST). These provide an attractive option for men looking for meaningful improvement in urinary symptoms whilst avoiding the risks of adverse effects, particularly with regards to maintaining sexual function.